BioSpace News Archive

Sensei Biotherapeutics, Inc., an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, announced the appointment of Kristian Humer, former managing director of Banking, Capital Markets & Advisory for the Global Healthcare team at Citigroup, Inc. as an independent director to the company’s board of directors, effective July 30, 2021.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Monday, August 9, 2021, to provide a corporate update and discuss details of the Company’s financial results for the quarter ended June 30, 2021.

Replimune Group, Inc., a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, announced that members from the Replimune management team will present and host investor meetings at the following two conferences:

T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, today announced the successful completion of a $110 million Series B financing.

Lumos Pharma, Inc. has announced that current Chief Operating Officer and Chief Scientific Officer, John McKew, PhD, was promoted to President of Lumos Pharma effective August 1, 2021 as part of the Company’s planned succession.

Happiness Biotech Group Limited today announced its financial results for the fiscal year ended March 31, 2021 .

Avidity Biosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) cleared the company to proceed with the Phase 1/2 MARINA™ clinical trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1).

Preclinical neuroscience company Delix Therapeutics (the “Company”), today announced the appointment of Dr. Brigitte Robertson as Chief Medical Officer.

First-of-its-kind initiative provides patients in India with access to remote opinions and consultations, using technology from India-based telemedicine provider iCliniq

Aridis Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 4,947,556 shares of the Company’s common stock